We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

144:HKEXGiken Holdings Co., Ltd. Analysis

Data as of 2026-03-14 - not real-time

¥320.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: Giken trades at 320 JPY, sitting just below the 20‑day SMA (326.75) but comfortably above the 50‑day (308.82) and 200‑day (243.92) averages, signalling a short‑term pullback within a longer‑term bullish trend. The RSI of 50.4 indicates neutral momentum, while a bearish MACD signal (negative histogram and signal line above the MACD line) points to near‑term downside pressure. Current price is nearer to the identified support at 290 JPY than the resistance at 369 JPY, and decreasing volume combined with a high 30‑day volatility of ~59% suggests price swings could be sharp.
Fundamental backdrop: The stock’s PE of 8.6 is dramatically lower than the industry average of 29.1, and a PB of 0.42 underscores deep value relative to book. A dividend yield of 0.34% with a payout ratio under 3% makes the dividend highly sustainable, though returns are modest. Weak ROE (5.3%) and ROA (2.9%) alongside net debt exceeding cash highlight execution risk, and the absence of analyst coverage adds uncertainty. Overall, Giken appears undervalued but faces short‑term technical headwinds and medium‑term execution challenges.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price approaching near‑term support at 290 JPY
  • Bearish MACD histogram indicating downside pressure
  • Decreasing volume and elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Deep valuation gap (PE 8.6 vs industry 29.1)
  • Sustainable dividend with very low payout ratio
  • Longer‑term uptrend confirmed by price above 50‑day and 200‑day SMAs

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Consistently low beta indicating defensive profile
  • Strong value metrics (PB 0.42, price below 20‑day SMA but above longer SMAs)
  • Potential for balance‑sheet improvement as cash offsets part of debt

Key Metrics & Analysis

Financial Health

Revenue Growth10.00%
Profit Margin12.37%
P/E Ratio8.6
ROE5.26%
ROA2.85%
Debt/Equity23.81
P/B Ratio0.4
Industry P/E29.1

Technical Analysis

TrendBullish
RSI50.4
Support¥290.00
Resistance¥369.00
MA 20¥326.75
MA 50¥308.82
MA 200¥243.92
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

GradeUndervalued
TypeValue
Dividend Yield0.34%

Risk Assessment

Beta0.29
Volatility59.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.